@coachdarianbates's testosterone dosing advice, fact-checked
Quick answer
The creator references the Bhasin et al. 2001 NEJM dose-escalation study to support recommending 200-600mg weekly testosterone enanthate as a performance cycle starting range. While the cited lean mass figures are broadly consistent with published data, the video conflates supraphysiologic performance dosing with TRT-range dosing without clinical screening, lab monitoring, or disclosure of established cardiovascular and hematologic risks. Any testosterone use above physiologic replacement levels requires prescriber oversight, baseline labs, and ongoing monitoring.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @coachdarianbates actually say?
The creator opened with aggressive bodybuilding-culture framing before pivoting to cite actual research. His core recommendation: start at 200mg of testosterone enanthate per week, increase in 50mg increments, and consider 300-600mg for bigger gains. He referenced a real dose-response study comparing 25, 50, 125, 300, and 600mg weekly doses over 12 weeks. He also argued that 100-200mg sits at "TRT levels," and that an aromatase inhibitor isn't necessarily needed at lower doses. The tone was performatively aggressive, but the second half of the video was more grounded than most steroid content on TikTok. That doesn't make it safe advice. Recommending supraphysiologic testosterone doses to an unscreened general audience, without labs, without a prescriber, and framed as a performance cycle, is a different animal than legitimate hormone optimization.
Does the science back this up?
The study he cited is real, and the numbers he pulled are largely accurate. Yes, the research shows a dose-response relationship. But context matters enormously here, and he left out most of it.
The study in question is Bhasin et al. (2001, New England Journal of Medicine), which suppressed endogenous testosterone production in 61 healthy men using a GnRH analog, then administered graded doses. The fat-free mass gains he quoted, roughly 3.4kg at 125mg and 7.9kg at 600mg, are consistent with the published data. So he read the study. Credit where it's due.
What he didn't mention: participants were eugonadal men whose natural production was chemically shut off first. The design was to isolate exogenous dose effects, not to model what happens when you stack supraphysiologic doses on top of existing testosterone. The cardiovascular, hematologic, and psychiatric risk data from that study, and from the broader literature, didn't make the cut in his video.
A 2023 meta-analysis by Lincoff et al. in the New England Journal of Medicine also found increased rates of nonfatal arrhythmia in testosterone-treated men, adding to a body of evidence that high-dose use carries real cardiac risk, particularly over repeated cycles.
What did they get wrong (or right)?
He got the study citation directionally right. The dose-response relationship between testosterone and lean mass gain is well-established, and his numbers track with Bhasin 2001. Calling 100-200mg a week "TRT levels" is also roughly consistent with clinical practice, though actual therapeutic dosing is individualized based on labs, not a blanket range.
Where he went wrong, and this matters, is in framing 300-600mg weekly as a reasonable starting point for a general audience without any clinical screening. At 600mg per week, you are well into supraphysiologic territory. Risks at that range include erythrocytosis, elevated hematocrit, dyslipidemia, suppression of the HPG axis, potential cardiac remodeling with long-term use, and mood instability. None of that appeared in the video.
His claim that you can skip an aromatase inhibitor at lower doses deserves nuance. Aromatization varies significantly between individuals based on body composition, genetics, and baseline estradiol. Blanket "you might not need an AI" advice to an anonymous audience is not the same as a clinician reviewing someone's labs and making that call.
The opening section, where he mocks beginners as "little girls" for starting at 250mg, is not just juvenile. It actively pushes people toward higher doses faster, which is the opposite of the harm-reduction framing he eventually adopts.
What should you actually know?
Testosterone at supraphysiologic doses is not a supplement decision. It is a medical intervention with real downstream consequences. The dose-response curve for muscle gain is real, but so is the dose-response curve for adverse effects.
If you are experiencing symptoms of low testosterone, including fatigue, low libido, cognitive fog, or mood changes, the appropriate starting point is bloodwork, not a TikTok cycle protocol. Legitimate TRT is prescribed based on total testosterone, free testosterone, LH, FSH, hematocrit, PSA, and other markers. It is managed over time with follow-up labs.
Performance-enhancement cycles at 300-600mg weekly are not TRT. They are pharmacological interventions with meaningful risk profiles, especially for younger men whose HPG axes have not fully matured, or anyone with undiagnosed cardiovascular risk factors.
The Bhasin 2001 study is worth reading in full, not just the lean mass numbers. The researchers also documented dose-dependent increases in prostate size and hematocrit, effects that compound with repeated cycling. That context didn't make the TikTok cut.
- Do not start any testosterone protocol without baseline bloodwork and a licensed prescriber reviewing your results.
- Aromatase inhibitor use should be guided by estradiol labs, not preemptive dosing or skipped based on a general recommendation.
- Post-cycle recovery, fertility impact, and HPG suppression are real considerations that this video did not address.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 4 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @coachdarianbates's testosterone dosing advice, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@coachdarianbates's testosterone dosing advice, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator references the Bhasin et al.
FormBlends verdict
The creator references the Bhasin et al. 2001 NEJM dose-escalation study to support recommending 200-600mg weekly testosterone enanthate as a performance cycle starting range. While the cited lean mass figures are broadly consistent with published data, the video conflates supraphysiologic performance dosing with TRT-range dosing without clinical screening, lab monitoring, or disclosure of established cardiovascular and hematologic risks. Any testosterone use above physiologic replacement levels requires prescriber oversight, baseline labs, and ongoing monitoring.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator references the Bhasin et al. 2001 NEJM dose-escalation study to support recommending 200-600mg weekly testosterone enanthate as a performance cycle starting range. While the cited lean mass figures are broadly consistent with published data, the video conflates supraphysiologic performance dosing with TRT-range dosing without clinical screening, lab monitoring, or disclosure of established cardiovascular and hematologic risks. Any testosterone use above physiologic replacement levels requires prescriber oversight, baseline labs, and ongoing monitoring.
- Bhasin et al. (2001, NEJM) confirmed a dose-response curve for testosterone and lean mass, but participants had endogenous production chemically suppressed, so the results don't map cleanly onto typical cycling scenarios.
- 600mg weekly testosterone is well into supraphysiologic territory and is associated with dose-dependent increases in hematocrit, prostate volume, and cardiovascular risk markers per the same 2001 NEJM study.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Bhasin et al. (2001, NEJM) confirmed a dose-response curve for testosterone and lean mass, but participants had endogenous production chemically suppressed, so the results don't map cleanly onto typical cycling scenarios.
- 600mg weekly testosterone is well into supraphysiologic territory and is associated with dose-dependent increases in hematocrit, prostate volume, and cardiovascular risk markers per the same 2001 NEJM study.
- Lincoff et al. (2023, NEJM) found elevated rates of nonfatal arrhythmia in testosterone-treated men, adding cardiac risk context that high-dose cycle content on TikTok routinely omits.
- Clinical TRT is dosed based on individual lab values including total testosterone, free testosterone, LH, FSH, and hematocrit, not a blanket 100-200mg weekly range.
- Aromatase inhibitor decisions should be based on measured estradiol levels, not skipped or applied as a default without knowing an individual's aromatization rate.
- HPG axis suppression from supraphysiologic testosterone use can persist after cycling ends, with fertility implications that the video did not address.
- No testosterone dose escalation should be undertaken without a licensed prescriber reviewing baseline and follow-up bloodwork.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dazz | BBuilding+Fitness Coach · TikTok creator
113.0K views on this video
Testosterone starting dose #testosteronereplacementtherapy #performanceenhancement #bodybuilding #roids
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dazz | BBuilding+Fitness Coach, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.